Literature DB >> 19064895

Prevalence and risk factors for selection of quinolone-resistant Escherichia coli strains in fecal flora of patients receiving quinolone therapy.

D Yagci1, F Yoruk, A Azap, O Memikoglu.   

Abstract

Patients taking quinolones as inpatients (n = 55) or outpatients (n = 40) and newly hospitalized patients who were not on quinolone therapy (n = 41) were assessed for fecal carriage of quinolone-resistant Escherichia coli (QREC) strains before and after therapy/hospitalization. Fluoroquinolone use in the previous 6 months was found to be a risk factor for QREC carriage before therapy/hospitalization. The prevalence of QREC strains in fecal flora increased steadily with the duration of quinolone therapy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19064895      PMCID： PMC2650567          DOI： 10.1128/AAC.01228-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the netherlands.

Authors:  W Goettsch; W van Pelt; N Nagelkerke; M G Hendrix; A G Buiting; P L Petit; L J Sabbe; A J van Griethuysen; A J de Neeling
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

Review 2.  Mechanism of action of and resistance to quinolones.

Authors:  D T Bearden; L H Danziger
Journal:  Pharmacotherapy       Date:  2001-10       Impact factor: 4.705

3.  Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis.

Authors:  S Perea; M Hidalgo; A Arcediano; M J Ramos; C Gomez; J Hornedo; C Lumbreras; D Folgueira; H Cortes-Funes; A Rodriguez-Noriega
Journal:  J Antimicrob Chemother       Date:  1999-07       Impact factor: 5.790

4.  Emergence and dissemination of quinolone-resistant Escherichia coli in the community.

Authors:  J Garau; M Xercavins; M Rodríguez-Carballeira; J R Gómez-Vera; I Coll; D Vidal; T Llovet; A Ruíz-Bremón
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.

Authors:  Hande Arslan; Ozlem Kurt Azap; Onder Ergönül; Funda Timurkaynak
Journal:  J Antimicrob Chemother       Date:  2005-09-20       Impact factor: 5.790

6.  Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis.

Authors:  Kalpana Gupta; Thomas M Hooton; Walter E Stamm
Journal:  J Antimicrob Chemother       Date:  2005-05-23       Impact factor: 5.790

7.  Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000.

Authors:  Marcus J Zervos; Ellie Hershberger; David P Nicolau; David J Ritchie; Lori K Blackner; Elizabeth A Coyle; Andrew J Donnelly; Stephen F Eckel; Robert H K Eng; Alexandra Hiltz; Arpi G Kuyumjian; William Krebs; Angee McDaniel; Patricia Hogan; Teresa J Lubowski
Journal:  Clin Infect Dis       Date:  2003-11-20       Impact factor: 9.079

8.  Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis.

Authors:  J Carratala; A Fernandez-Sevilla; F Tubau; M A Dominguez; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection.

Authors:  G Kahlmeter; P Menday; O Cars
Journal:  J Antimicrob Chemother       Date:  2003-11-12       Impact factor: 5.790

10.  Prior antibiotics and risk of antibiotic-resistant community-acquired urinary tract infection: a case-control study.

Authors:  Sharon Hillier; Zoe Roberts; Frank Dunstan; Chris Butler; Anthony Howard; Stephen Palmer
Journal:  J Antimicrob Chemother       Date:  2007-05-30       Impact factor: 5.790
  10 in total
  12 in total

1.  Emergence of resistant Klebsiella pneumoniae in the intestinal tract during successful treatment of Klebsiella pneumoniae lung infection in rats.

Authors:  Anne-Sylvie Kesteman; Agnès Perrin-Guyomard; Michel Laurentie; Pascal Sanders; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Antimicrobial resistance in more than 100,000 Escherichia coli isolates according to culture site and patient age, gender, and location.

Authors:  José Miguel Sahuquillo-Arce; María Selva; Hèctor Perpiñán; Miguel Gobernado; Carmen Armero; Antonio López-Quílez; Francisco González; Hermelinda Vanaclocha
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

Review 3.  Clinical importance and epidemiology of quinolone resistance.

Authors:  Eu Suk Kim; David C Hooper
Journal:  Infect Chemother       Date:  2014-12-29

4.  Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility.

Authors:  Jennifer H Han; Warren B Bilker; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Neil O Fishman; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2013-08-23       Impact factor: 3.254

5.  Detection of fluoroquinolone-resistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy.

Authors:  Michael A Liss; Amy N Peeples; Ellena M Peterson
Journal:  J Clin Microbiol       Date:  2010-12-22       Impact factor: 5.948

6.  Efficacy of Single Dose of Fosfomycin Versus a Five-Day Course of Ciprofloxacin in Patients With Uncomplicated Urinary Tract Infection.

Authors:  Muhammad Mujeeb Hassan; Moeena Malik; Rabia Saleem; Amna Saleem; Khurram Zohaib; Adnan Younas Malik; Maham Javaid
Journal:  Cureus       Date:  2022-05-09

7.  The impact of a nationwide antibiotic restriction program on antibiotic usage and resistance against nosocomial pathogens in Turkey.

Authors:  Adalet Altunsoy; Cenk Aypak; Alpay Azap; Önder Ergönül; Ismail Balık
Journal:  Int J Med Sci       Date:  2011-05-24       Impact factor: 3.738

Review 8.  Infection after transrectal ultrasound-guided prostate biopsy.

Authors:  Seung-Ju Lee
Journal:  Korean J Urol       Date:  2015-04-06

9.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14

10.  Do we really know the prevalence of multi-drug resistant Escherichia coli in the territorial and nosocomial population?

Authors:  Stefano Picozzi; Cristian Ricci; Maddalena Gaeta; Alberto Macchi; Emmanuel Dinang; Gaia Paola; Milvana Tejada; Elena Costa; Giorgio Bozzini; Stefano Casellato; Luca Carmignani
Journal:  Urol Ann       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.